全文获取类型
收费全文 | 6518篇 |
免费 | 370篇 |
国内免费 | 15篇 |
专业分类
耳鼻咽喉 | 103篇 |
儿科学 | 209篇 |
妇产科学 | 64篇 |
基础医学 | 642篇 |
口腔科学 | 96篇 |
临床医学 | 545篇 |
内科学 | 1475篇 |
皮肤病学 | 89篇 |
神经病学 | 489篇 |
特种医学 | 305篇 |
外科学 | 1147篇 |
综合类 | 98篇 |
一般理论 | 4篇 |
预防医学 | 263篇 |
眼科学 | 267篇 |
药学 | 524篇 |
中国医学 | 23篇 |
肿瘤学 | 560篇 |
出版年
2024年 | 3篇 |
2023年 | 48篇 |
2022年 | 122篇 |
2021年 | 246篇 |
2020年 | 122篇 |
2019年 | 209篇 |
2018年 | 228篇 |
2017年 | 176篇 |
2016年 | 203篇 |
2015年 | 188篇 |
2014年 | 315篇 |
2013年 | 371篇 |
2012年 | 550篇 |
2011年 | 611篇 |
2010年 | 315篇 |
2009年 | 292篇 |
2008年 | 399篇 |
2007年 | 435篇 |
2006年 | 373篇 |
2005年 | 346篇 |
2004年 | 303篇 |
2003年 | 326篇 |
2002年 | 229篇 |
2001年 | 70篇 |
2000年 | 45篇 |
1999年 | 49篇 |
1998年 | 46篇 |
1997年 | 35篇 |
1996年 | 24篇 |
1995年 | 25篇 |
1994年 | 23篇 |
1993年 | 16篇 |
1992年 | 25篇 |
1991年 | 20篇 |
1990年 | 21篇 |
1989年 | 22篇 |
1988年 | 3篇 |
1987年 | 12篇 |
1986年 | 8篇 |
1985年 | 3篇 |
1984年 | 5篇 |
1981年 | 3篇 |
1980年 | 3篇 |
1979年 | 3篇 |
1978年 | 3篇 |
1977年 | 5篇 |
1976年 | 4篇 |
1975年 | 3篇 |
1970年 | 3篇 |
1969年 | 4篇 |
排序方式: 共有6903条查询结果,搜索用时 15 毫秒
131.
132.
Day‐case device implantation—A prospective single‐center experience including patient satisfaction data
下载免费PDF全文
![点击此处可从《Pacing and clinical electrophysiology : PACE》网站下载免费的PDF全文](/ch/ext_images/free.gif)
133.
Purpose
Hepatitis C, a chronic disease with deadly consequences, is no longer predominantly a disease of older people.Methods
A limited search was conducted of the relevant literature on 2 topics: (1) the impact of hepatitis C on infants exposed by vertical transmission; and (2) the impact of hepatitis C infection on infected children and adolescents. The findings were supplemented by the first-hand experience of the authors.Findings
Young people, including women of childbearing age, infants, children, and adolescents, are being especially affected by hepatitis C infection secondary to the intravenous drug use and opioid epidemic. Unfortunately, estimates of disease in young populations are all misleading because universal screening has not been implemented.Implications
Lack of implementation of policies for screening and therapy on most affected populations will be responsible for perpetuation of this infection. In the era of highly effective therapy and a regimen that is approved by the US Food and Drug Administration for children, this outcome is unacceptable. 相似文献134.
135.
136.
Bommena Hanumantha Rao Inti Venkata Subramanyeswara Rao Vysyaraju Ravi Kanth Korrapati Venkata Vara Prasada Rao K. Balamurali Krishna Bethanabatla Syama Sundar 《Scientia pharmaceutica》2015,83(3):465-478
Drug product purity and potency are of most significance in the regulatory market as we notice many recalled batches worldwide, particularly in the US and Japan. Olmesartan Medoxomil is an anti-hypertensive drug. The present invention relates to a process for the preparation of Olmesartan Medoxomil with 99.9% purity in an overall 62% yield. The synthesis includes three isolations and one purification with easy plant operations. This process describes the formation and control of each individual impurity in all stages. This process for Olmesartan Medoxomil and its intermediates is competent for industrial production in very short reaction time intervals with an appreciable yield and high purity. 相似文献
137.
138.
139.
Kane Jeremy C. Sharma Anjali Murray Laura K. Chander Geetanjali Kanguya Tukiya Skavenski Stephanie Chitambi Chipo Lasater Molly E. Paul Ravi Cropsey Karen Inoue Sachi Bosomprah Samuel Danielson Carla Kmett Chipungu Jenala Simenda Francis Vinikoor Michael J. 《AIDS and behavior》2022,26(2):523-536
AIDS and Behavior - This randomized controlled trial tested the efficacy of a multi-session, evidence-based, lay counselor-delivered transdiagnostic therapy, the Common Elements Treatment Approach... 相似文献
140.
Jasbir Makker Hassan Tariq Kishore Kumar Madhavi Ravi Danial Haris Shaikh Vivien Leung Umar Hayat Muhammad T Hassan Harish Patel Suresh Nayudu Sridhar Chilimuri 《World journal of gastroenterology : WJG》2021,27(6):523-533
BACKGROUND Nonalcoholic fatty liver disease(NAFLD)and type-2 diabetes mellitus(T2DM)have an intricate bidirectional relationship.Individuals with T2DM,not only have a higher prevalence of non-alcoholic steatosis,but also carry a higher risk of progression to nonalcoholic steatohepatitis.Experts still differ in their recommendations of screening for NAFLD among patients with T2DM.AIM To study the prevalence of NAFLD and advanced fibrosis among our patient population with T2DM.METHODS During the study period(November 2018 to January 2020),59 adult patients with T2DM and 26 non-diabetic control group individuals were recruited prospectively.Patients with known significant liver disease and alcohol use were excluded.Demographic data and lab parameters were recorded.Liver elastography was performed in all patients.RESULTS In the study group comprised of patients with T2DM and normal alanine aminotransferase levels(mean 17.8±7 U/L),81%had hepatic steatosis as diagnosed by elastography.Advanced hepatic fibrosis(stage F3 or F4)was present in 12%of patients with T2DM as compared to none in the control group.Patients with T2DM also had higher number of individuals with grade 3 steatosis[45.8%vs 11.5%,(P<0.00001)and metabolic syndrome(84.7%vs 11.5%,P<0.00001)].CONCLUSION A significant number of patients with T2DM,despite having normal transaminase levels,have NAFLD,grade 3 steatosis and advanced hepatic fibrosis as measured by liver elastography. 相似文献